Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Newbury Pharmaceuticals Q4 - Reaping the rewards

Newbury Pharmaceuticals

Redeye provides a research update following the Q4 report recently published by Newbury. Following continued progress in portfolio expansion, regulatory approvals and product launches, the company managed to achieve impressive sales figures for the quarter. However, as we believe that the performance of individual quarters are quite volatile in Newbury’s current state and expected strong sales figures given the previously postponed orders, we do not make any drastic changes to our estimates. We reiterate our base case valuation of SEK8.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Newbury Pharmaceuticals Q4 - Reaping the rewards

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.